Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2005-8-15
pubmed:abstractText
Experiments were carried out in canine ventricular trabeculae loaded with aequorin to investigate the effects of levosimendan {(R)-([4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono)-propanedinitrile} on contractile force and Ca(2+) transients in normal and acidotic conditions. The concentration-response curve for the positive inotropic effect (PIE) of levosimendan was bell-shaped, that is, it declined markedly at 10(-4) M after achieving the maximum at 10(-5) M in normal (pH(o)=7.4) and acidotic conditions (pH(o)=6.6). The positive inotropic effect (PIE) of levosimendan up to 10(-5) M was associated with an increase in Ca(2+) transients and a shift of the relationship of Ca(2+) transients and force to the left of that of elevation of [Ca(2+)](o). Levosimendan at 10(-4) M elicited a negative inotropic effect (NIE) in association with a further increase in Ca(2+) transients, and during washout Ca(2+) transients increased further, while the force was abolished before both signals recovered to the control. In acidotic conditions, the relationship of Ca(2+) transients and force during the application of levosimendan in normal conditions was essentially unaltered, whereas the PIE was suppressed due to attenuation of the increase in Ca(2+) transients. In summary, in intact canine ventricular myocardium, levosimendan elicits a dual inotropic effect: at lower concentrations, it induces a PIE by a combination of increases in Ca(2+) transients and Ca(2+) sensitivity, while at higher concentrations it elicits an NIE due to a decrease in Ca(2+) sensitivity. Acidosis inhibits the PIE of levosimendan due to suppression of the increase in Ca(2+) transients in response to the compound.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-10892669, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-10913591, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-11504803, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-12198318, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-12382073, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-1934345, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2061846, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2193525, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2417748, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2427830, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2433073, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2621616, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-2867838, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-6329076, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-6410050, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-6758036, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-7713348, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-7788868, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-7853225, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-7961805, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8382578, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8576932, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8897445, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8907127, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8945898, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8996203, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-8996207, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9144257, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9211815, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9231037, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9415267, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9686764, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9689586, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9724303, http://linkedlifedata.com/resource/pubmed/commentcorrection/15951828-9815868
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
145
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1143-52
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.
pubmed:affiliation
Department of Cardiovascular Pharmacology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't